​

Evommune (EVMN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

EVMN Stock Forecast

Evommune (EVMN) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $27.83, with a high of $50.00 and a low of $18.00. This represents a 236.92% increase from the last price of $8.26.

EVMN Stock Rating

Evommune stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

EVMN Price Target Upside V Benchmarks

TypeNameUpside
StockEvommune236.92%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4416
Avg Price Target$22.75$22.75$39.44
Last Closing Price$8.26$8.26$8.26
Upside/Downside175.42%175.42%377.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26452--11
Aug, 26352--10
Jul, 26352--10
Jun, 2628---10
May, 2628---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2026Alex ThompsonStifel Nicolaus$30.00$10.92174.73%263.20%
Sep 09, 2026Raymond James$18.00$11.1261.87%117.92%
Sep 09, 2026Leerink Partners$22.00$10.89102.02%166.34%
Sep 09, 2026Brian AbrahamsRBC Capital$21.00$10.5599.05%154.24%
Jun 30, 2026Morgan Stanley$26.00$15.0572.76%214.77%
May 26, 2026Mitchell KapoorH.C. Wainwright$50.00$22.87118.63%505.33%
May 11, 2026Morgan Stanley$55.00$24.50124.49%565.86%
Feb 18, 2026Judah FrommerMorgan Stanley$54.00$31.0673.86%553.75%
Feb 10, 2026Evercore ISI$55.00$30.1082.72%565.86%
Feb 10, 2026Mitchell KapoorH.C. Wainwright$65.00$28.81125.62%686.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 18, 2026Cantor FitzgeraldOverweightOverweighthold
Sep 09, 2026RBC CapitalOutperformOutperformhold
Aug 26, 2026NeedhamBuyinitialise
Aug 03, 2026H.C. WainwrightNeutralNeutralhold
Jun 30, 2026H.C. WainwrightBuyNeutraldowngrade
Jun 29, 2026William BlairOutperformMarket Performdowngrade
May 26, 2026H.C. WainwrightBuyBuyhold
May 11, 2026Morgan StanleyOverweightOverweighthold
Feb 18, 2026Morgan StanleyOverweightOverweighthold
Feb 10, 2026Evercore ISIOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-2.27$-2.18--
Avg Forecast$-5.15$-5.42$-2.70$-2.81
High Forecast$-5.15$-2.52$-2.35$-2.81
Low Forecast$-5.15$-12.84$-3.36$-2.81
Surprise %-55.92%-59.78%--

Revenue Forecast

$0 $4M $8M $12M $16M $20M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$7.00M$13.00M--
Avg Forecast$3.00M$6.33M$6.25M$19.21M
High Forecast$3.00M$13.00M$6.25M$19.21M
Low Forecast$3.00M$3.00M$6.25M$19.21M
Surprise %133.33%105.37%--

Net Income Forecast

$-400M $-330M $-260M $-190M $-120M $-50M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-66.81M$-68.87M--
Avg Forecast$-154.85M$-231.00M$-86.60M$-84.52M
High Forecast$-154.85M$-75.80M$-70.68M$-84.52M
Low Forecast$-154.85M$-386.20M$-101.06M$-84.52M
Surprise %-56.86%-70.19%--

EVMN Forecast FAQ

Is Evommune stock a buy?

Evommune stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Evommune is a favorable investment for most analysts.

What is Evommune's price target?

Evommune's price target, set by 5 Wall Street analysts, averages $27.83 over the next 12 months. The price target range spans from $18 at the low end to $50 at the high end, suggesting a potential 236.92% change from the previous closing price of $8.26.

How does Evommune stock forecast compare to its benchmarks?

Evommune's stock forecast shows a 236.92% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Evommune over the past three months?

  • September 2026: 36.36% Strong Buy, 45.45% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Evommune’s EPS forecast?

Evommune's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.7, marking a 23.85% increase from the reported $-2.18 in 2025. Estimates for the following years are.

What is Evommune’s revenue forecast?

Evommune's average annual revenue forecast for its fiscal year ending in December 2026 is $6.25M, reflecting a -51.92% decrease from the reported $13M in 2025. The forecast for.

What is Evommune’s net income forecast?

Evommune's net income forecast for the fiscal year ending in December 2026 stands at $-86.6M, representing an 25.74% increase from the reported $-68.87M in 2025. Projections indicate .